Scroll Back to Top

Study number 8533-669

1 Night, 10 Follow up Visits & 3 Calls


Aug 21 2024-Oct 24 2024


Daytona Beach, Florida




Male or Female




Cohort 7

Study Details

Mirikizumab (the study drug) is an investigational drug that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with moderately to severely active ulcerative colitis (a bowel disease that causes inflammation in the digestive tract). The study drug is also being developed for the potential treatment of autoimmune diseases (a condition in which the immune system mistakenly attacks the body) and Crohn’s disease (a bowel disease that affects the lining of the digestive tract). 

The use of the study drug in this study is investigational. An investigational use is one that is not approved by the FDA. 

The purposes of this study are to look at: • How much of the study drug enters the circulation of the body (and so is able to have an active effect) when given as 1 subcutaneous (under the skin) injection compared to 2 subcutaneous injections. • The safety and tolerability of the study drug when given as 1 subcutaneous injection compared to 2 subcutaneous injections. 

Fortrea Daytona Beach, FL is recruiting for: 

- Healthy Adults, age 18-65 

- Body Mass Index between 18-34

- Study involves 1 overnight stay, 10 follow-up visits and 3 phone calls 

- Compensation up to $6,805 may be provided for time and participation 

- Refer a friend to receive $400 per qualified referral

Additional Details

Call Now to Schedule Your Screening Appointment!

Cohort 7:
Check-in: Aug 21
Check-out: Aug 22

Follow up Visits: Aug 24, 26, 29, Sep 1, 5, 12, 19, Oct 3, 17, 31

Phone Calls: Sep 26, Oct 10, 24

BMI Calculator



Feet Inches